ACSL4 and diabetes mellitus: Some studies have found that when the ACSL4 inhibitor rosiglitazone (ROSI) is used in diabetic nephropathy mice, it may inhibit the inflammatory response, thereby inhibiting ferroptosis, and finally improving the damage of renal tubular cells in a high-glucose environment (Wang et al., 2020), which also provides some ideas for ACSL4 as a potential therapeutic target for diabetes.